Catheter Precision, Inc. VTAK
0.15
(0.01)
(6.25%)
as of 25 Sep
- Market cap
- $3.0M
- P/E
- 0.0×
Follow VTAK
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.03 | 0.00 | 0.00 | 0.00 |
P/S ratio |
4.56 | 2.41 | 2.00 | 1.23 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(1.52) | (1.31) | (0.79) | (0.82) | |
P/B ratio |
0.52 | 0.30 | 0.24 | 0.14 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
3.59 | 6.13 | 4.55 | 2.01 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.27) | (0.60) | (0.58) | (0.41) | |
EV/FCF |
(0.27) | (0.60) | (0.57) | (0.41) | |
Quick Ratio |
0.41 | 0.06 | 0.04 | 0.15 | |
Current Ratio |
0.46 | 0.10 | 0.06 | 0.19 | |
Net Debt/EBITDA |
0.30 | (0.32) | (1.53) | (0.44) | |
Debt/Assets |
5.09% | 19.41% | 9.16% | 8.92% | |
Debt/Equity |
0.20 | 0.46 | 0.35 | 0.19 | |
Asset Turnover |
0.03 | 0.04 | 0.04 | 0.06 | |
Operating CF/Net income |
0.97 | 0.26 | 0.92 | 1.12 | |
Capex/Depreciation |
0.00 | 0.00 | (0.01) | (0.02) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
122.12% | 137.82% | 34.49% | 13.94% | |
Selling, General and Administrative Expense of Revenue |
1,306.64% | 1,157.98% | 592.36% | 383.81% | |
Intangible Assets out of Total Assets |
0.89 | 0.96 | 0.91 | 0.86 | |
Share Based Compensation of Revenue |
30.97% | 33.19% | 14.81% | 26.10% | |
Graham Net Nets |
(4.98) | (4.46) | (11.15) | (7.32) | |
Graham Number |
104.77 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
3,964.10% | (1,019.04%) | (1,306.37%) | (810.59%) | |
Free Cash Flow Yield |
(290.42%) | (420.38%) | (396.03%) | (398.46%) | |
Revenue per Share |
0.17 | 0.22 | 0.20 | 0.37 | |
Operating CF per Share |
(1.65) | (1.40) | (1.28) | (1.03) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Free Cash Flow per Share |
(1.65) | (1.40) | (1.28) | (1.04) | |
Cash per Share |
1.56 | 0.08 | 0.20 | 0.66 | |
Shareholders Equity per Share |
4.88 | 6.15 | 4.18 | 6.19 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.88 | 6.15 | 4.18 | 6.19 | |
Free Cash Flow |
(2.18) | (1.51) | (2.80) | (2.88) | |
Working Capital |
(2.86) | (3.52) | (18.49) | (10.94) | |
Capital Expenditures |
0.00 | 0.00 | (0.01) | (0.01) | |
Net Current Asset Value |
(16.56) | (8.82) | (24.68) | (17.22) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.01 | |
Net Profit Margin |
(996.02%) | (2,427.73%) | (703.94%) | (250.74%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.12 | 0.11 | 0.17 | 0.12 | |
Average Payables |
0.89 | 0.86 | 0.86 | 1.13 | |
Average Inventory |
0.03 | 0.06 | 0.07 | 0.07 | |
Average Assets |
26.11 | 21.82 | 29.94 | 31.22 | |
Average Common Equity |
9.64 | 9.20 | 8.54 | 11.84 |
Columns are period end dates